Evidence map›Paper›PMID 40626067›Full record

ArticleRSC advances2025

Development and

Mbongeni Shungube, Nakita Reddy, Terisha Ghazi, Kimberleigh B Govender, Ravesh Singh, Afsana Kajee, Anil Chuturgoon, Hendrik G Kruger, Per I Arvidsson, Dileep Tiwari and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mbongeni ShungubeCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.
Nakita ReddyCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.ORCID https://orcid.org/0000-0003-4428-2241
Terisha GhaziSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal Durban 4041 South Africa.
Kimberleigh B GovenderCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.ORCID https://orcid.org/0000-0003-2372-5365
Ravesh SinghSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal Durban 4041 South Africa.
Afsana KajeeSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal Durban 4041 South Africa.
Anil ChuturgoonSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal Durban 4041 South Africa.ORCID https://orcid.org/0000-0003-4649-4133
Hendrik G KrugerCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.ORCID https://orcid.org/0000-0003-0606-2053
Per I ArvidssonCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.ORCID https://orcid.org/0000-0002-9453-6812
Dileep TiwariCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.
Thavendran GovenderDepartment of Chemistry, University of Zululand Private Bag X1001 KwaDlangezwa 3886 South Africa.
Tricia NaickerCatalysis and Peptide Research Unit, University of KwaZulu-Natal Durban 4001 South Africa govenderthav@icloud.com naickert1@ukzn.ac.za +27 312601845.ORCID https://orcid.org/0000-0002-7134-6258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is a critical global issue, particularly against β-lactam antibiotics, which comprise over 60% of prescriptions. Metallo-β-lactamases (MBLs) are especially concerning as they inactivate nearly all β-lactams, except monobactams. Unlike serine-β-lactamases (SBLs), for which inhibitors exist, there are no clinically approved MBL inhibitors; only taniborbactam is in pre-registration. This study introduces eight new MBL inhibitors (13a-f, 14a-b), designed using a 1,4,7-triazacyclononane (NO3PY) chelator linked to a β-lactam. These inhibitors restored the efficacy of meropenem, reducing its minimum inhibitory concentration (MIC) against MBL-expressing pathogens to <2 mg L

Identifiers

PMID40626067
PMCPMC12230942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.